Joseph Slattery

Mr. Slattery serves on the Board of Replimune Group, Inc., Morphic Therapeutic and CVRx®. He previously served as the Executive Vice President and Chief Financial Officer of TransEnterix, Inc. from October 2013 through December 2019. Mr. Slattery served as Executive Vice President and Chief Financial Officer of Baxano Surgical, Inc. from April 2010 until September 2013. Mr. Slattery served as a member of the Baxano Surgical Board of Directors from November 2007 until April 2010 and resigned in connection with his appointment as an officer. From February 1996 through August 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, a molecular diagnostics company that was acquired by Qiagen, N.V. in August 2007, including from October 2006 through August 2007 as Chief Financial Officer and Senior Vice President of Finance and Information Systems. Mr. Slattery served on the Board of Directors of Micromet, Inc., a publicly-held biopharmaceutical company, and Exosome Diagnostics, Inc., a privately-held molecular diagnostics company. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.